Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 2Sarcoma 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Hodgkin Disease 2Burkitt Lymphoma 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Teratoma 1Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia 1Heart Failure 1Glioma 1Fallopian Tube Neoplasms 1Desmoplastic Small Round Cell Tumor 1Dendritic Cell Sarcoma, Interdigitating 1Choriocarcinoma 1Central Nervous System Neoplasms 1Cardiotoxicity 1

Interventions

Carboplatin 18Paclitaxel 17Bevacizumab 17olaparib 8Specimen Handling 7liposomal doxorubicin 6pembrolizumab 5Taxes 5Biopsy 5cemiplimab 4Magnetic Resonance Spectroscopy 4sarilumab 3niraparib 3mirvetuximab soravtansine 3Topotecan 3Standard of Care 3Letrozole 3Gemcitabine 3Cisplatin 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2palbociclib 2abemaciclib 2Temozolomide 2Surgical Procedures, Operative 2Practice Guidelines as Topic 2Poly(ADP-ribose) Polymerase Inhibitors 2Immunoglobulin G 2Fulvestrant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Fallopian Tube Neoplasms × pegfilgrastim × Clear all
NCT06690775 2025-12-23

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

TORL Biotherapeutics, LLC

Phase 2 Recruiting
230 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡